ANKHD1 and cancer: Furthermore, at a clinical level, the increased expression of ANKHD1 has been demonstrated to result in a reduction in the relapse-free survival of patients, greater tumour infiltration, increased metastasis, larger tumours, resulting in poorer prognosis, more aggressive growth, and a decrease in the survival rate of patients, regardless of the type of cancer [53,54,61].